Details of the Drug

General Information of Drug (ID: DM9NSWT)

Drug Name

Guanethidine

Synonyms

Abapresin; Dopam; Dopom; Eutensol; Guanethidinum; Guanetidina; Ismelin; Isobarin; Octadin; Octadine; Octatensin; Octatensine; Oktadin; Oktatensin; Oktatenzin; Sanotensin; Guanethidine Sulphae; Guanethidine sulfate; Ismelin sulfate; Apo-Guanethidine; Guanethidine (INN); Guanethidine [INN:BAN]; Guanethidinum [INN-Latin]; Guanetidina [INN-Spanish]; Apo-Guanethidine (TN); Beta-1-Azacyclooctylethylguanidine; Guanethidine Sulfate (1:1); Guanethidine Sulfate (2:1); Su 5864 sulfate (1:1); N-(2-Perhydroazocin-1-ylethyl)guanidine; ((2-Hexahydro-1(2H)-azocinyl)ethyl)guanidine; (2-(Octahydro-1-azocinyl)ethyl)guanidine; 1-(2-azocan-1-ylethyl)guanidine; 1-[2-(azocan-1-yl)ethyl]guanidine; 2-(1'-Azacyclooctyl)ethylguanidine; 2-(1-N,N-Heptamethyleneimino)ethylguanidine; 2-[2-(azocan-1-yl)ethyl]guanidine

Indication

Disease Entry	ICD 11	Status	REF
Moderate and severe hypertension	BA00.Z	Approved	[1]
------------------------------------------------------------------------------------

Therapeutic Class

Antihypertensive Agents

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

198.31

Logarithm of the Partition Coefficient (xlogp)

0.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption: The oral absorption of drug is 3-30% []
BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 1: high solubility and high permeability [2]
Clearance: The renal clearance of drug is 56 mL/min []
Half-life: The concentration or amount of drug in body reduced by one-half in 1.5 days [3]
Metabolism: The drug is metabolized via the liver []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 4.20042 micromolar/kg/day [4]

Chemical Identifiers

Formula: C10H22N4
IUPAC Name: 2-[2-(azocan-1-yl)ethyl]guanidine
Canonical SMILES: C1CCCN(CCC1)CCN=C(N)N
InChI: InChI=1S/C10H22N4/c11-10(12)13-6-9-14-7-4-2-1-3-5-8-14/h1-9H2,(H4,11,12,13)
InChIKey: ACGDKVXYNVEAGU-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 3518
ChEBI ID: CHEBI:5557
CAS Number: 55-65-2
DrugBank ID: DB01170
TTD ID: D0N3PE

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Adrenergic neuron (AD neuro)	TTT04VN	NOUNIPROTAC	Blocker	[5]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Phosphatidylcholine translocator ABCB4 (ABCB4)	OTE6PY83	MDR3_HUMAN	Gene/Protein Processing	[6]
Pro-neuropeptide Y (NPY)	OT4ICV3P	NPY_HUMAN	Protein Interaction/Cellular Processes	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Guanethidine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Methylene blue	DMJAPE7	Moderate	Antagonize the effect of Guanethidine when combined with Methylene blue.	Acquired methaemoglobinaemia [3A93]	[8]
Cariprazine	DMJYDVK	Moderate	Additive hypotensive effects by the combination of Guanethidine and Cariprazine.	Bipolar disorder [6A60]	[9]
Isocarboxazid	DMAF1NB	Moderate	Antagonize the effect of Guanethidine when combined with Isocarboxazid.	Depression [6A70-6A7Z]	[8]
OPC-34712	DMHG57U	Moderate	Additive hypotensive effects by the combination of Guanethidine and OPC-34712.	Depression [6A70-6A7Z]	[9]
ITI-007	DMUQ1DO	Moderate	Additive hypotensive effects by the combination of Guanethidine and ITI-007.	Insomnia [7A00-7A0Z]	[9]
Ozanimod	DMT6AM2	Moderate	Antagonize the effect of Guanethidine when combined with Ozanimod.	Multiple sclerosis [8A40]	[8]
Safinamide	DM0YWJC	Moderate	Antagonize the effect of Guanethidine when combined with Safinamide.	Parkinsonism [8A00]	[8]
Rasagiline	DM3WKQ4	Moderate	Antagonize the effect of Guanethidine when combined with Rasagiline.	Parkinsonism [8A00]	[8]
Quetiapine	DM1N62C	Moderate	Additive hypotensive effects by the combination of Guanethidine and Quetiapine.	Schizophrenia [6A20]	[9]
Aripiprazole	DM3NUMH	Moderate	Additive hypotensive effects by the combination of Guanethidine and Aripiprazole.	Schizophrenia [6A20]	[9]
Iloperidone	DM6AUFY	Moderate	Additive hypotensive effects by the combination of Guanethidine and Iloperidone.	Schizophrenia [6A20]	[9]
Paliperidone	DM7NPJS	Moderate	Additive hypotensive effects by the combination of Guanethidine and Paliperidone.	Schizophrenia [6A20]	[9]
Molindone	DMAH70G	Moderate	Additive hypotensive effects by the combination of Guanethidine and Molindone.	Schizophrenia [6A20]	[9]
Amisulpride	DMSJVAM	Moderate	Additive hypotensive effects by the combination of Guanethidine and Amisulpride.	Schizophrenia [6A20]	[9]
Asenapine	DMSQZE2	Moderate	Additive hypotensive effects by the combination of Guanethidine and Asenapine.	Schizophrenia [6A20]	[9]
-----------


⏷ Show the Full List of 15 DDI Information of This Drug

References

1	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Characterization of bradykinin-induced endothelium-independent contraction in equine basilar artery. J Vet Pharmacol Ther. 2009 Jun;32(3):264-70.
6	Evaluating the Role of Multidrug Resistance Protein 3 (MDR3) Inhibition in Predicting Drug-Induced Liver Injury Using 125 Pharmaceuticals. Chem Res Toxicol. 2017 May 15;30(5):1219-1229. doi: 10.1021/acs.chemrestox.7b00048. Epub 2017 May 4.
7	Release and functional role of neuropeptide Y as a sympathetic modulator in human saphenous vein biopsies. Peptides. 2004 Jan;25(1):53-64. doi: 10.1016/j.peptides.2003.11.001.
8	Darcy PF, Griffin JP "Interactions with drugs used in the treatment of depressive illness." Adverse Drug React Toxicol Rev 14 (1995): 211-31. [PMID: 8845455]
9	Aronowitz JS, Chakos MH, Safferman AZ, Lieberman JA "Syncope associated with the combination of clozapine and enalapril." J Clin Psychopharmacol 14 (1994): 429-30. [PMID: 7884028]